Genentech Self-Portrait For 2005
Executive Summary
Genentech has set ambitious targets for growth over the next six years - if Roche does not exercise its option to buy out the remainder of the company
You may also be interested in...
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005
Genentech Eyes Top Oncology Spot By 2010; No Near-Term Avastin Competitor
Genentech believes the first competitor to its oncologic Avastin in the angiogenesis market is "years away.